Ramsden, Dale A. http://orcid.org/0000-0003-1575-4748
Carvajal-Garcia, Juan http://orcid.org/0000-0001-7257-3674
Gupta, Gaorav P.
Article History
Accepted: 21 July 2021
First Online: 14 September 2021
Competing interests
: G.P.G. receives research funding from Breakpoint Therapeutics, which is developing inhibitors of polymerase-θ. D.A.R. has a materials transfer agreement with Artios Pharma, and is using an Artios Pharma compound that inhibits polymerase-θ for research purposes, with no financial compensation.